Media Articles Related to Zelboraf (Vemurafenib)
Potential Solution To Melanoma's Resistance To Vemurafenib
Source: Abortion News From Medical News Today [2012.03.01]
Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma. Vemurafenib resistance is characterized by a diminished apoptosis (programmed cancer cell death) response.
Published Studies Related to Zelboraf (Vemurafenib)
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic
melanoma patients with a BRAF(V600E) mutation. 
Following Phase I and II studies revealing vemurafenib to be a safe potent
inhibitor of mutated BRAF in patients with metastatic melanoma, a multicenter
randomized Phase III trial was carried out to compare vemurafenib with
dacarbazine in treatment-naive patients.
Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the
treatment of metastatic melanoma. 
CONCLUSIONS: Vemurafenib offers a novel, first-line, personalized therapy for
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. 
metastatic melanoma with the BRAF V600E mutation... CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free
Clinical Trials Related to Zelboraf (Vemurafenib)
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer [Recruiting]
The goal of this clinical research study is to learn about how vemurafenib may affect
certain biomarkers in patients with PTC. Biomarkers are in the blood/tissue and may be
related to your reaction to the study drug. The safety of this drug will also be studied.
Vemurafenib is designed to block the BRAF gene mutation. This mutation causes cancer and
cancer growth. By blocking this mutation, the drug may kill the cancer cells with the
mutation and/or stop the tumor from growing.
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of
vemurafenib that can be given in combination with either everolimus or temsirolimus. The
safety of these drug combinations will also be studied.
Vemurafenib is designed to block BRAFV600 inside the cancer cells, which is a mutation that
is involved in cancer cell growth.
Temsirolimus and everolimus are designed to block the growth of cancer cells, which may
cause cancer cells to die.
Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma [Not yet recruiting]
In this study, the drugs being used are vemurafenib and bevacizumab. Vemurafenib works by
blocking a protein called B-RAF. Researchers have found that a large number of melanomas
have mutations (changes) in the BRAF gene. The BRAF gene codes for a protein called B-RAF,
which is involved in sending signals in cells that can lead to cell growth. Research has
determined that mutations in the BRAF gene at the V600 position cause a change in the B-RAF
protein that can drive the growth and spread of melanoma cells. Vemurafenib works by
preventing these altered B-RAF proteins from working, and thereby may block the growth and
spread of cancer cells in patients with melanoma. Information from prior research studies
suggests that this drug can shrink melanoma tumors in the majority of patients, delay tumor
growth and prolong overall survival relative to standard chemotherapy. As a consequence,
vemurafenib received FDA approval in August 2011 for the treatment of patients with
B-RAFV600 mutant melanoma.
Bevacizumab is a humanized monoclonal antibody (a type of protein that is normally made by
the immune system to help defend the body from infection and cancer) directed against
vascular endothelial growth factor (VEGF). VEGF is a potent growth factor with a
well-defined role in normal and abnormal blood vessel formation. In the cancer setting, VEGF
promotes the growth of blood vessels that bring nutrients to tumor cells. Its expression by
the tumor has been associated with worse outcome in patients with a number of tumor types
including melanoma. In laboratory experiments, bevacizumab inhibits the growth of several
different types of human cancer cells by blocking the effects of VEGF. Bevacizumab has been
approved by the FDA for use in combination with first line chemotherapies for treatment of
patients with colorectal, breast and lung cancer; however, bevacizumab has not been approved
for use in patients with metastatic melanoma.
The purpose of this research study is to determine the effectiveness of using vemurafenib
and bevacizumab together relative to vemurafenib alone. This study will investigate whether
using both study drugs lengthens the amount of time before a patient's melanoma worsens,
increases the number of people whose melanoma responds to treatment and what side effects
are associated with the use of both drugs together rather than separately.
Vemurafenib and Sorafenib in Advanced Cancer [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the
combination of ZelborafTM (vemurafenib) with Nexavar® (sorafenib) or Xalkori® (crizotinib)
that can be given to patients with advanced cancer. The safety of these drugs will also be
Vemurafenib is designed to block a protein called BRAFV600E inside the cancer cells, which
is involved in cancer cell growth.
Sorafenib is designed to block the function of important proteins in and outside of cancer
cells. These proteins are involved in cancer cells growth and new blood vessel development.
Crizotinib is designed to block certain abnormal genes found in cancer cells. This may
cause the cancer cells to die.
Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas [Not yet recruiting]
This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a
recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory
gliomas containing the BRAFV600E mutation.
Reports of Suspected Zelboraf (Vemurafenib) Side Effects
Decreased Appetite (106),
Disease Progression (73),
Diarrhoea (66), more >>